Health Committee - Fourth Report
Top-up fees
Here you can browse the report together with the Proceedings of the Committee. The published report was ordered by the House of Commons to be printed 30 April 2009.
Contents
Terms of Reference
Summary
1 Introduction
2 The nature and scale of the problem
The role of NICE and PCTs in determining access to drugs
Criticisms of the system
The role of Primary Care Trusts
The withdrawal of NHS care for patients who chose to purchase additional treatment
Conclusions
3 Addressing the problem
Richards' recommendations to minimise the need to purchase drugs
Richards' recommendations to ensure the separation of NHS and private care
The response of the Department and NICE to the Richards Report
Guidance on separating NHS and private care
Review of guidance for NICE Appraisal Committees
The Pharmaceutical Price Regulation Scheme
Conclusions
4 The consequences of separating NHS and private treatment
Potential problems in separating NHS and private treatment
Patients with the same condition, on the same ward, receiving different treatment
Problems with ensuring separation and the quality of care
Additional costs to the NHS
Has the Department's decisions opened the way for a "core service" in the NHS?
Conclusions
5 The potential consequences of the proposals to make more drugs available
The review of guidance for NICE Appraisal Committees
The questionable basis for what amounts to raising the QALY for end-of-life drugs
Inconsistencies will remain between PCTs
Funding end-of-life treatments will not be affordable
The Pharmaceutical Price Regulation Scheme
Patient access / risk sharing schemes
Conclusions
6 Conclusions
Conclusions and recommendations
Formal Minutes
Witnesses
List of written evidence
List of further written evidence
List of Reports from the Health Committee
Oral and Written Evidence
Thursday 29 January 2009
Thursday 12 February 2009
Written Evidence
| 
